Abstract
Background Dilated cardiomyopathy (DCM) is a progressive myocardial disorder characterized by impaired cardiac contraction and ventricular dilation. Some patients with DCM could manifest improvement in these abnormalities called left ventricular reverse remodeling (LVRR). However, the detailed association between genotypes and clinical outcomes, including LVRR, particularly among pediatric patients, remains uncertain.
Methods We prospectively enrolled pediatric patients with DCM from Japanese multi-institutional centers between 2014 and 2023. We identified DCM-related genes and explored the association between gene variants and clinical outcomes, including LVRR, which was defined as any increase in left ventricular ejection fraction during the observation period.
Results A total of 123 pediatric patients (62 males; mean age of 8 months [range, 1–51 months]) were retrospectively enrolled. There were 50 pathogenic variants in 45 patients (35.0%). The most identified gene was MYH7 (14.0%), followed by RYR2 (12.0%), and TPM1 (8.0%). A novel variant in the CASZ1 gene (NM_001079843.2 c.3356G>A, p. Trp1119Ter) was identified. LVRR was achieved in 47.5% of patients. In patients with sarcomere gene variants, the left ventricular ejection fraction remained unchanged (31.4% to 39.8%, P = 0.1913), whereas it significantly increased in patients with non-sarcomere gene variants (33.4% to 47.8%, P = 0.0466) and in patients without gene variants (33.6% to 54.1%, P = 0.003).
Conclusions Pediatric patients with DCM exhibited a marked genetic heterogeneity with a different landscape from adults with DCM. LVRR was not uniform across functional gene groups, opening the door to tailor-made gene-guided prediction in pediatric patients with DCM.
What is new?
Younger patients had predominance for DCM and risk factors for survival.
LVRR occurrence was lower in the sarcomere gene group, and cardiac function failed to improve.
What are the clinical implications?
LVRR was not uniform across functional gene groups, which opens the door to the adoption of an individualized prediction approach in DCM according to the genetic features.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Keiichi Hirono is supported by grants from The Ministry of Education, Culture, Sports, Science, and Technology in Japan (Grant-in-Aid for Scientific Research No. 22K07932).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki, as reflected by the a priori approval of the Research Ethics Committee of the University of Toyama, Japan.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data that supports the findings of this study are available in the supplementary material of this article.
Abbreviations
- DCM
- dilated cardiomyopathy
- ECG
- electrocardiogram
- HF
- heart failure
- LV
- left ventricle
- LVRR
- left ventricular reverse remodeling
- MACE
- major adverse cardiac events
- NGS
- next-generation sequencing
- PCR
- polymerase chain reaction
- BNP
- brain natriuretic peptide
